Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors.

出版年份 2021 全文链接

标题

作者

关键词

出版物

Volume 39, Issue 15_suppl, Pages 2613-2613

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2021-06-02

DOI

10.1200/jco.2021.39.15_suppl.2613

Discuss science. Find collaborators. Network.

Join a conversation

Explore over 38,000 international journals covering a vast array of academic fields.